AU2913400A - Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof - Google Patents

Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Info

Publication number
AU2913400A
AU2913400A AU29134/00A AU2913400A AU2913400A AU 2913400 A AU2913400 A AU 2913400A AU 29134/00 A AU29134/00 A AU 29134/00A AU 2913400 A AU2913400 A AU 2913400A AU 2913400 A AU2913400 A AU 2913400A
Authority
AU
Australia
Prior art keywords
mage
mhc
class
immunogenic peptides
peptides presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29134/00A
Inventor
Paolo Dellabona
Maria Pia Protti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND, Fondazione Centro San Raffaele del Monte Tabor filed Critical SAN RAFFAELE CENTRO FOND
Publication of AU2913400A publication Critical patent/AU2913400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU29134/00A 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof Abandoned AU2913400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A0396 1999-02-26
IT1999MI000396A IT1309584B1 (en) 1999-02-26 1999-02-26 IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
PCT/EP2000/001458 WO2000052045A2 (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Publications (1)

Publication Number Publication Date
AU2913400A true AU2913400A (en) 2000-09-21

Family

ID=11382063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29134/00A Abandoned AU2913400A (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Country Status (6)

Country Link
EP (1) EP1161443A2 (en)
JP (1) JP2002538166A (en)
AU (1) AU2913400A (en)
CA (1) CA2364002A1 (en)
IT (1) IT1309584B1 (en)
WO (1) WO2000052045A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
FR2837837B1 (en) 2002-03-28 2006-09-29 Roussy Inst Gustave PEPTIDE EPITOPES COMMON TO ANTIGENS OF THE SAME MULTIGENIC FAMILY
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2008053573A1 (en) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remedy for malignant neoplasm
TWI546381B (en) * 2014-05-30 2016-08-21 中央研究院 Aptamer targeting mage-a3 peptide and uses thereof
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69435292D1 (en) * 1993-03-05 2010-06-17 Epimmune Inc METHOD FOR THE PRODUCTION OF IMMUNOGENOUS HLA-A2.1-BINDING PEPTIDES
EP1012238A4 (en) * 1997-01-31 2003-03-05 Epimmune Inc Peptides and peptide-loaded antigen presenting cells for the activation of ctl
JP3840268B2 (en) * 1997-07-15 2006-11-01 タカラバイオ株式会社 Cytotoxic T lymphocytes
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP2002507397A (en) * 1998-03-13 2002-03-12 エピミューン，インコーポレイティド HLA binding peptides and uses thereof

Also Published As

Publication number Publication date
WO2000052045A3 (en) 2001-01-04
JP2002538166A (en) 2002-11-12
WO2000052045A2 (en) 2000-09-08
EP1161443A2 (en) 2001-12-12
IT1309584B1 (en) 2002-01-24
CA2364002A1 (en) 2000-09-08
ITMI990396A1 (en) 2000-08-26

Similar Documents

Publication Publication Date Title
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
IL158107A0 (en) Human papillomaviruses vaccine
AU2001244675A1 (en) Aids virus vaccine with the use of sendai virus vector
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
PT1150712E (en) Human papilloma virus vaccine formulations
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
AU4139801A (en) Controlled delivery of antigens
IL148247A (en) Vaccine composition and uses thereof
AU1812001A (en) Cotton transcription factors and their uses
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU715620C (en) Therapeutic methods and uses
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU6600300A (en) Pneumococcal vaccines
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
GB2370772B (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
AU1467101A (en) Myb transcription factors and uses thereof
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2002210407A1 (en) Therapeutic vaccine formulations containing chitosan
EP1168918A4 (en) Vaccines and gene therapy compositions and methods of making and using the same
AU5977700A (en) Vaccines
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU1911301A (en) Novel bacterial isolate and the preparation and use of its active metabolites

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase